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Advanced Practice

Nonalcoholic Fatty Liver Disease and
The PNPLA3 Gene
Lori Houghton-Rahrig, Debra Schutte, Jenifer I. Fenton, and Jennifer Awad

onalcoholic fatty liver disease (NAFLD) is a rapidly
emerging worldwide public
health concern strongly associated
with obesity, insulin resistance/diabetes type 2, and the metabolic syndrome (Younossi et al., 2011). It is
the most common cause of liver disease in the world (World Gastroenterology Organisation [WGO],
2012). Defined as a total liver weight
comprised of more than 5% fat,
NAFLD can progress from simple
fatty liver disease to nonalcoholic
steatohepatitis with or without fibrosis, liver cirrhosis, liver cancer, or
liver failure resulting in premature
death (Levene & Goldin, 2012). The
development and progression of
NAFLD is influenced by genetic and
environmental factors that may
have implications for health (Romeo
et al., 2008; Romeo et al., 2009;
Valenti et al., 2010). A description of
NAFLD is provided in this article,
with information about the genetic
basis of NAFLD and potential implications of genetic health information related to NAFLD. Nurses’ critical role in health promotion, disease
prevention, and management of
chronic disease in persons with
NAFLD also will be discussed.

N

Description of Health
Problem
History
Nonalcoholic fatty liver disease
first was described in the 1950s following liver biopsy in patients who
did not drink alcohol but developed
liver cirrhosis with fatty liver
changes similar to those of alcoholic
fatty liver (Westwater & Fainer,
1958). In 1980, Dr. Ludwig of the

Nonalcoholic fatty liver disease, a potentially fatal obesity-related condition, affects more than 70 million people in the United States. Nurses
are well-positioned to impact this genetically influenced disease by
increasing awareness, providing patient education, and advocating for
affected persons.
Mayo Clinic named this condition
of fatty liver changes in obese persons nonalcoholic steatohepatitis
(NASH); it now is recognized as the
inflammatory stage of NAFLD
(Ludwig, Viggiano, McGill, & Oh,
1980). In recent years, NAFLD has
become more prevalent, coinciding
with the obesity epidemic (WGO,
2012).

Natural History
Incidence and Prevalence
The incidence of NAFLD is difficult to estimate as no diagnostic laboratory tests are available to confirm
its presence (WGO, 2012). Although
persistent elevation of liver enzymes,
such as aspartate transaminase and
alanine aminotransferase, often is
used to trigger evaluation workup for
a diagnosis of NAFLD, estimates of
the true incidence of this condition
are difficult because normal liver
enzymes may be present in people
with NAFLD (Rafiq & Younossi,

2009; WGO, 2012). Unlike other
equally common diseases (e.g., obesity, diabetes), NAFLD is not a diagnosis found in national databases
such as the National Health and
Examination Survey (NHANES).
Nonetheless, NAFLD is considered a
global health concern with an estimated worldwide prevalence from
2.8% (diagnosed by aminotransferase elevation) to 46% (diagnosed
by imaging or liver biopsy) (Lazo &
Clark, 2008).
Nonalcoholic fatty liver disease
and obesity have been observed in
many developed countries (WGO,
2012). Worldwide prevalence of obesity is estimated at 1.46 billion adults,
suggesting over 292 million adults
have NAFLD (Vernon, Baranova, &
Younossi, 2011). The U.S. prevalence
of NAFLD is estimated at 63 million
people, compared to 47 million with
metabolic syndrome and 25 million
with diabetes mellitus as diseases
commonly associated with NAFLD
(American Heart Association [AHA],
2010; Centers for Disease Control
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TABLE 1.
NAFLD by Race/Ethnicity
Race/Ethnicity

Prevalence

African American

45%

Caucasian

33%

Hispanic

24%

African American

35.1%

Caucasian

44.4%

Hispanic

58.3%

African American

13.5%

Caucasian

17.8%

Hispanic

24.1%

African American

11.6%

Caucasian

12.5%

Hispanic

21.2%

African American

23.1%

Caucasian

29.8%

Hispanic

39.4%

Participants in Study
2,349 - to reflect Dallas, TX
population; 32.1% Caucasian,
48.3% African American,
17.5% Hispanic

Browning et al.,
2004
Victor et al., 2004

Study Type
Secondary analysis of Dallas Heart
Study participants in whom H-MRS
was available

328; majority of patients with
Williams et al.,
NAFLD were male (58.9%),
2011
significantly older, and heavier
with higher prevalence of HTN
and diabetes

Prospective study

12,454; participants of
NHANES

Lazo et al., 2013

Ultrasonography from NHANESNAFLD defined as presence of
hepatic steatosis on ultrasonography
in the absence of elevated alcohol
usage

9,675; participants of
NHANES

Schneider, Lazo,
Selvin, & Clark,
2013

Cross-sectional study of NHANES

3,846; participants of
NHANES

Smits, Ioannou,
NAFLD determined by increased
Boyko, &
liver fat by ultrasonography
Utzschneider, 2013 data derived from cross-sectional
study (NHANES)

American Indian
31% of
26,166
and Alaskan Native patients with
chronic liver
disease
2% of general population

and Prevention, 2013; U.S. Census
Bureau, 2013; WGO, 2012). Nonalcoholic fatty liver disease particularly affects persons who are obese;
approximately 75%-92% of them
have NAFLD (WGO, 2012). Prevalence projections from the
NHANES (1988-2008), which used
elevated liver enzymes and absence
of other liver disease to determine a
NAFLD diagnosis, indicate over 50%
of U.S. residents will have NAFLD by
2030 (Baranova et al., 2011; Younossi
et al., 2011). This underscores the
need for research of this rapidly
growing disease.

Race/Ethnicity, Sex, and Age
Nonalcoholic fatty liver disease
occurs in both sexes with nearly
equal frequency, and in children as
well as in adults (Sanyal, 2011;
Vernon et al., 2011). It is more common in the 4th-6th decades of life,

102

Study

Fischer, Bialek,
Retrospective cross-sectional study
Homan, Livingston, from electronic medical records of
& McMahon, 2009 Alaska Native Medical Center

but occurs over time (Vernon et al.,
2011). In a recent cohort study of
39,500 adults, increasing age was
identified as an independent predictor of NAFLD (Younossi et al., 2011).
A prevalence study found 46% of
adults (mean age 54.6) had NAFLD
on ultrasound (Williams et al.,
2011). Likewise, NAFLD prevalence
increases in children as they age
(Feldstein et al., 2009).
Nonalcoholic fatty liver disease
occurs across all racial and ethnic
groups. Because some frequencies
are higher than others, race/ethnicity may be a predictor of NAFLD
(WGO, 2012). See Table 1 for frequency of NAFLD by race/ethnicity.
While American Indian and
Alaskan-native populations have a
high prevalence of diabetes and obesity as co-morbidities commonly
associated with NAFLD, little NAFLDrelated research has been conducted

in these groups. However, a population study of Alaskan-native and
American Indians with chronic liver
disease found NAFLD was the second
leading cause of chronic liver disease
(Fischer, Bialek, Homan, Livingston,
& McMahon, 2009). NAFLD was
determined to be the cause of chronic liver disease in 31% of the patients
(n=1,886), but was found in only
2% of the general population
(n=26,166). Further research is warranted in these populations to assess
the prevalence of NAFLD in all stages
of the disease.

Average Duration
Although NAFLD is a progressive
disorder, the average duration of the
disease is unknown. It is believed to
develop over time (Baranova et al.,
2011). A longitudinal study followed
persons across all stages of the
NAFLD illness trajectory. Lower sur-
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vival rates were observed in people
with NAFLD who presented with
NASH or cirrhosis at initial diagnosis
(Feldstein et al., 2009). This finding is
especially concerning for obese children with NAFLD who may die prematurely as a result of disease progression to end-stage liver disease.

Progression
Nonalcoholic fatty liver disease is
characterized by four stages of progression. Simple fatty liver disease is
the first stage, in which fat is found in
the hepatocytes. The second stage is
an inflammatory state of the liver
(NASH), which may occur with or
without fibrosis. Nonalcoholic steatohepatitis may progress to cirrhosis,
one of possible end stages of NAFLD
in which scarring of liver tissue
results in deterioration of liver function (National Institute of Diabetes
and Digestive and Kidney Diseases,
2008). Cirrhosis may lead to liver
cancer or liver failure. While not all
people with NAFLD will progress to
end-stage liver failure or liver cancer,
approximately 600,000 people will
progress to the cirrhosis stage of this
disease which can result in premature death (WGO, 2012; Younossi et
al., 2011).

Clinical Features
The clinical symptoms of NAFLD
are not understood fully. Historically, NAFLD has been considered an
asymptomatic disease, although
some evidence indicates fullness or
discomfort may occur in the right
upper quadrant, as well as fatigue
(WGO, 2012). Studies in children
have reported symptoms of fatigue,
sleep disturbances, and sadness
resulting in decreased health-related
quality of life; this suggests adults
may have symptoms that are yet to
be attributed to NAFLD (Kistler et al.,
2010).
Persons with NAFLD also may
have features of the metabolic syndrome, including obesity (especially
upper-body obesity), hyperglycemia,
low high-density lipoproteins, and
hypercholesterolemia (AHA, 2011).
In children with NAFLD and metabolic syndrome, signs and symptoms of fatigue, abdominal pain,

hepatomegaly, splenomegaly, and
acanthosis nigricans may be present
(Feldstein et al., 2009). Persons in the
later stages of NAFLD such as liver
cirrhosis may exhibit jaundice, itching, ascites, peripheral edema, bruising, and esophageal varices (American Liver Foundation, 2011). More
research is needed to determine the
symptoms of NAFLD; nurses can use
such information to implement
early weight loss strategies and manage patient symptoms in the later
stages of disease (Houghton-Rahrig
et al., 2013).

Current Prognostic and
Diagnostic Capabilities
Patients often present to their primary care providers with elevated
liver enzymes, leading to an evaluation for NAFLD and possible referral
to a gastroenterologist (Rafiq &
Younossi, 2009). Liver biopsy is the
gold standard for staging and grading
the disease (WGO, 2012). Because
only a small percentage of people
receive a liver biopsy due to potential
risks of the procedure, early diagnosis
and staging of NAFLD are difficult. As
a result, NAFLD often is found incidentally through imaging for other
conditions such as acute cholecystitis
(Rafiq & Younossi, 2009).
While imaging may detect
NAFLD, it is inadequate in determining the stage and grade of disease
because tests, such as ultrasound, CT
scan, or MRI, cannot detect fibrosis
(Mehta, Thomas, Bell, Johnston, &
Taylor-Robinson, 2008). Other scanning modalities are emerging, such
as the Fibroscan (Echosens of Inner
Mongolia; Furui Medical Science
Co., France), which measures liver
stiffness. Liver stiffness is thought to
be influenced by the presence of
fibrosis in advanced disease (Wong
et al., 2008).

fructose and transfats should be
encouraged. People with NAFLD
should obtain moderately vigorous
exercise 3-4 times a week. Use of
statins, such as atorvastatin (Lipitor®)
or pravastatin (Pravachol®), is recommended to control hyperlipidemia
(WGO, 2012).

Genetics and NAFLD
Mode of Inheritance
Nonalcoholic fatty liver disease is a
multifactorial disorder resulting from
the combined effects of genetics and
environment. Several lines of evidence point to a genetic contribution
to NAFLD. First, NAFLD is highly heritable (h²=0.850; standard error,
0.325, p<0.0001). In a study of obese
children with liver biopsy-confirmed
NAFLD, 59% (n=17 of 29) of their siblings had NAFLD compared to 17%
(n=2 of 12) of siblings of obese children without NAFLD. Of obese children with liver biopsy-confirmed
NAFLD, 78% (n=43 of 55) of their parents also had NAFLD compared
to 37% (n=7 of 19) of parents of
obese children without NAFLD
(Schwimmer et al., 2009). Strong heritability of CT scan-confirmed NAFLD
was found in three large family-based
cohorts: Amish (0.27, SE 0.08;
N=880), Family Heart (0.27, SE 0.04;
N=2767), and Framingham Heart
Studies (0.26, SE 0.04, N=3070)
(Speliotes et al., 2011). Further, the
studies by Schwimmer and colleagues
(2009) and Speliotes and co-authors
(2011) noted familial aggregation
consistent with a complex genetic
disorder. In addition, a case report
from Cleveland Clinic identified an
extended family with confirmed
NAFLD spanning three generations
and suspected NAFLD occurring in
over five generations (Carter-Kent &
Feldstein, 2010). High heritability and
familial aggregation suggest NAFLD
has a genetic component.

Current Treatments

Susceptibility Genes

Current treatments target weight
loss through diet, exercise, lifestyle
modification, and/or bariatric surgery to reverse NAFLD (Mummadi,
Kasturi, Chennareddygari, & Sood,
2008; WGO, 2012). Diets devoid of

Given evidence for heritability,
research has attempted to identify
specific genes that contribute to
increased risk or susceptibility to disease. A Patatin-like phospholipase
domain-containing 3 gene (PNPLA3)
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has been identified as a risk gene for
NAFLD (Romeo et al., 2008). The
association between NAFLD and the
PNPLA3 (rs738409) polymorphism
was discovered using the Dallas Heart
Study data, a genetic association
study (n=2,111) measuring 9,222
nonsynonymous DNA variants
(Romeo et al., 2008; Victor et al.,
2004). Romeo and others (2008)
identified a polymorphism in the
PNPLA3 (rs738409) gene that is associated strongly with fat content in
the liver (p=5.9 x 10¯¹º). In addition,
this polymorphism was associated
with fat content in the liver after
adjusting for body mass index, diabetes, alcohol use, and ancestry
(p=7.0 x 10¯¹ ).
The nonsynonymous polymorphism (rs738409) in the PNPLA3
gene is a single base pair substitution
of guanine for cytosine, resulting in
an amino acid change from
isoleucine to methionine at codon
148 position (Romeo et al., 2008).
Located on chromosome 22 (22q
13.31), PNPLA3 (rs738409) encodes
triacylglycerol lipase, a protein that
is “expressed highest in hepatocytes,
followed by skin and adipocytes”
(National Center for Biotechnology
Information, 2013; Online Mendelian Inheritance in Man, 2011, para.
2). Triacylglycerol lipase mediates triacylglycerol hydrolysis in adipocytes, a process involved in the balance of energy usage/storage in the
adipocytes and thought to be regulated by nutrition (Huang et al.,
2010). This polymorphism is hypothesized to inhibit triglyceride
hydrolysis, resulting in deposits of
fat in the liver (He et al., 2010;
Romeo, Huang-Doran, Baroni, &
Kotronen, 2010).
Several studies support the findings of the Romeo (2008) study
(Davis et al., 2010; Kantartzis et al.,
2009; Kotronen et al., 2009; Rotman,
Koh, Zmuda, Kleiner, & Liang, 2010;
Sookoian et al., 2009; Valenti et al.,
2010). For example, several implications of the risk (G) allele of the
PNPLA3 (rs738409) gene have been
reported. The risk (G) allele of the
PNPLA3 (rs738409) gene was associated with earlier presentation of
NAFLD in children (Rotman et al.,
2010). In adults, NAFLD severity
104

(e.g., cirrhosis with hepatocellular
carcinoma) increased with the presence of two copies of the risk (G) alleles of the PNPLA3 (rs738409) gene
(odds ratio 1.76, 95% CI 1.06-2.92,
p<0.05), and is considered an independent predictor of hepatocellular
carcinoma occurrence, especially in
men (Falleti et al., 2011; Sookoian et
al., 2009; Valenti et al., 2010). The
frequency of the risk (G) allele of the
PNPLA3 (rs738409) gene also was
associated with alcoholic fatty liver
disease and increasing severity of
liver disease, suggesting the PNPLA3
(rs738409)-G allele is associated with
liver injury (Tian, Stokowski,
Kershenobich, Ballinger, & Hinds,
2010). Romeo and colleagues (2008)
also discovered a variant of the
PNPLA3 gene (rsrs6006460)-T was
associated with lower hepatic fat.
This variant was more common in
African Americans that in European
Americans or Hispanics, suggesting
the PNPLA3 gene (rsrs6006460)-T
polymorphism may act as a protective polymorphism that prevents
excess fat storage in the liver.
Interestingly, Browning and colleagues (2004) were the first researchers to note lower presence of
NAFLD in African Americans than in
European Americans and Hispanics.
In addition to the frequency of
the PNPLA3 (rs738409)-G allele,
other genes or loci correlate with the
disease-associated risk of NAFLD. A
smaller study of 95 Asian-Indian
males found a significant association
with the APO3 gene variant alleles
(Petersen et al., 2010). Of males who
were carriers of the AP03 gene variants C-482T, T-455C, or both, 38%
(n=36 of 95) had NAFLD; those with
the wild-type variant, that is the variant that occurs most often in the
general population, did not
(p<0.001). Together, these data suggest NAFLD is a multifactorial disease with potentially numerous
genetic influences, most notably, the
PNPLA3 (rs738409) polymorphism
(Romeo et al., 2008). Further genetic
and environmental research is needed to aid in early identification of
patients with NAFLD and those at
risk for NAFLD progression for early
referral; findings could contribute to
tailored interventions.

Implications of Genetic
Information for NAFLD
Individual Health
Implications
As noted earlier, the risk (G) allele
of the PNPLA3 (rs738409) gene is
associated with severity of disease in
both children and adults, hepatocellular carcinoma in adults, and an
earlier presentation of the disease in
children (Falleti et al., 2011; Rotman
et al., 2010; Sookoian et al., 2009;
Valenti et al., 2010). The use of genotyping for the PNPLA3 (rs738409-G)
allele may provide a means to identify persons at risk for NAFLD progression to NASH or liver cirrhosis/liver
cancer (Romeo et al., 2010). Early
identification of persons at risk for
NAFLD progression would allow earlier intervention.
Hispanics have a genetic predisposition to NAFLD that may explain
the higher percentage of Hispanics
with NAFLD in the secondary analyses of the Dallas Heart Study
(Browning et al., 2004; Romeo et al.,
2008; Tian et al., 2010). Davis and
others (2010) found an environmental link with a genetically predisposed population. Hispanic children
with two copies of the PNPLA3
(rs738409-G) risk allele are more likely to have more hepatic fat accumulation when dietary sugar intake is
high than those with one or no
copies of the risk (G) allele. Although
this study had a cross-sectional
design, findings suggest treatment
based on genotype, such as reduced
sugar intake for persons with two
copies of the “at risk” (G) allele, may
be beneficial.
Further research is needed to
determine how genotyping of persons with NAFLD may guide effective treatment for NAFLD. Treatment
recommendations based solely on
genotype currently are premature.
However, future research may suggest specific dietary or medication
recommendations on this basis.

Public Health Implications
The use of the PNPLA3 gene variant can provide a means to study the
molecular components of NAFLD
such as the causes of disease progres-
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sion. Romeo and others (2010) suggested the PNPLA3 gene can be used
to discern the interaction between
related metabolic conditions, such as
insulin resistance and dyslipidemia,
vs. NAFLD. Speliotes and colleagues
(2011) laid the foundation for future
functional studies of polymorphisms
related to NAFLD and other associated metabolic conditions.
Kollerits and co-authors (2010)
found a correlation between the
PNPLA3 (rs738409) gene variant and
elevation in liver enzymes. Future
clinical uses of the correlation
between elevated ALT and the
PNPLA3 (rs738409) gene may provide a means to measure interventions. These researchers also noted a
potential pharmaceutical target for
drug trials in the treatment of
NAFLD.
Genotyping may be done for children and adults who may be at risk
for NAFLD and NAFLD progression,
such as persons with obesity or a
family history of NAFLD progression, and those with Hispanic ancestry (Tian et al., 2010). Family interventions could be employed early to
teach healthy eating habits, and the
importance of exercise and frequent
follow up, especially in those with
one or two copies of the risk (G)
allele.

Nursing Implications
Nurses are well-positioned to
employ interventions that will
impact NAFLD in hospital and community settings. Awareness of
NAFLD through patient education is
essential to help patients and their
families understand the prevalence
and severity of this obesity-related
disease. Advanced practice nurses
(APNs) can provide screening and
counseling of patients with NAFLD
or genetic predisposition to NAFLD.
School nurses may develop health
promotion programs with increased
physical activity and healthy eating
to prevent obesity-related NAFLD
and decrease NAFLD in children
with existing disease. Physical activity studies of school-aged boys and
girls developed by Robbins, Talley,
Wu, and Wilbur (2010) may be help-

ful in developing programs to prevent and treat obesity-related
NAFLD in children. Doctorally prepared nurses can assess and implement system changes to facilitate
such an activity program (American
Association of Colleges of Nursing,
2006). In addition, nurses can teach
and role-model obesity sensitivity in
all settings.
Medical-surgical nurses also can
help patients identify symptoms
that signal disease progression in the
later stages of disease through
patient assessment, follow up, and
patient education (Borneman et al.,
2010). Nurses can assist patients and
families in obtaining timely interventions through self-monitoring
through the use of a symptom management toolkit (Given, Given, &
Espinosa, 2007). Such interventions
may increase the amount of time
between discharge and re-admission
for older adults through symptom
monitoring, as seen in the classic
randomized control trial by Naylor
and colleagues (1999). Advanced
practice nurses can provide case
management services to patients
with advanced disease to navigate
the health care system. They can
work closely with medical-surgical
nurses to monitor medications for
patients with impaired liver function
and common comorbid conditions
(Nguyen, Cutie, & Pham, 2010).

Conclusion
Nonalcoholic fatty liver disease is
a worldwide health concern that may
result in premature death if allowed
to progress. Identification of the
PNPLA3 (rs738409-G) gene variant
offers opportunities for improved risk
prediction in persons who may
develop NAFLD. Nurses can facilitate
health promotion, disease prevention, and chronic disease management for persons with NAFLD.
Further research is needed to understand the mechanism underlying the
PNPLA3 genetic association as well as
the genetic basis of symptoms in
order to develop improved risk prediction models and subsequent tailored interventions (HoughtonRahrig et al., 2013).
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